3D tumor cultures for drug resistance and screening development in clinical applications

被引:7
作者
Peng, Zheng [1 ]
Lv, Xiaolan [2 ]
Sun, Hao [3 ]
Zhao, Lina [4 ]
Huang, Shigao [5 ]
机构
[1] Liuzhou Tradit Chinese Med Hosp, Dept Clin Lab, Liuzhou, Guangxi, Peoples R China
[2] Liuzhou Matern & Child Healthcare Hosp, Dept Clin Lab, Liuzhou, Guangxi, Peoples R China
[3] Autonomous Univ Madrid, Fac Sci, Spainish Natl Res Council, Consejo Super Invest Cient, Madrid 28049, Spain
[4] Fourth Mil Med Univ, Xijing Hosp, Dept Radiat Oncol, State Key Lab Holist Integrat Management Gastroint, Xian, Peoples R China
[5] Fourth Mil Med Univ, Xijing Hosp, Dept Radiat Oncol, Xian, Peoples R China
基金
中国国家自然科学基金;
关键词
Cancer resistance; 3D tumor culture model; Organoids; Tumor microenvironment; Drug screening; PATIENT-DERIVED ORGANOIDS; CELL-CULTURE; CANCER; DISCOVERY; MODELS; FIBROBLASTS; MEDICINE; SYSTEMS;
D O I
10.1186/s12943-025-02281-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor drug resistance presents a growing challenge in medical practice, particularly during anti-cancer therapies, where the emergence of drug-resistant cancer cells significantly complicates clinical treatment. In recent years, three-dimensional (3D) tumor culture technology, which more effectively simulates the in vivo physiological environment, has gained increasing attention in tumor drug resistance research and clinical applications. By mimicking the in vivo cellular microenvironment, 3D tumor culture technology not only recapitulates cell-cell interactions but also more faithfully reproduces the biological effects of therapeutic agents. Consequently, 3D tumor culture technology is emerging as a crucial tool in biomedical and clinical research. We summarize the benefits of 3D culture models and organoid technology, explore their application in the realm of drug resistance, drug screening, and personalized therapy, and discuss their potential application prospects and challenges in clinical transformation, with the aim of providing insights for optimizing cancer treatment strategies and advancing precision therapy.
引用
收藏
页数:16
相关论文
共 102 条
[1]   Scaffold-based 3D cell culture models in cancer research [J].
Abuwatfa, Waad H. ;
Pitt, William G. ;
Husseini, Ghaleb A. .
JOURNAL OF BIOMEDICAL SCIENCE, 2024, 31 (01)
[2]   Comparative Analysis of 3D Bladder Tumor Spheroids Obtained by Forced Floating and Hanging Drop Methods for Drug Screening [J].
Amaral, Robson L. F. ;
Miranda, Mariza ;
Marcato, Priscyla D. ;
Swiech, Kamilla .
FRONTIERS IN PHYSIOLOGY, 2017, 8
[3]  
Ansori Arif Nm, 2023, Narra J, V3, pe184, DOI 10.52225/narra.v3i2.184
[4]   Global Disparities of Cancer and Its Projected Burden in 2050 [J].
Bizuayehu, Habtamu Mellie ;
Ahmed, Kedir Y. ;
Kibret, Getiye Dejenu ;
Dadi, Abel F. ;
Belachew, Sewunet Admasu ;
Bagade, Tanmay ;
Tegegne, Teketo Kassaw ;
Venchiarutti, Rebecca L. ;
Kibret, Kelemu Tilahun ;
Hailegebireal, Aklilu Habte ;
Assefa, Yibeltal ;
Khan, Md Nuruzzaman ;
Abajobir, Amanuel ;
Alene, Kefyalew Addis ;
Mengesha, Zelalem ;
Erku, Daniel ;
Enquobahrie, Daniel A. ;
Minas, Tsion Zewdu ;
Misgan, Eyaya ;
Ross, Allen G. .
JAMA NETWORK OPEN, 2024, 7 (11)
[5]   A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells [J].
Borges, Sahra ;
Doeppler, Heike R. ;
Storz, Peter .
BREAST CANCER RESEARCH AND TREATMENT, 2014, 144 (01) :79-91
[6]   Liver organoid as a 3D in vitro model for drug validation and toxicity assessment [J].
Brooks, Anastasia ;
Liang, Xiaowen ;
Zhang, Yonglong ;
Zhao, Chun-Xia ;
Roberts, Michael S. ;
Wang, Haolu ;
Zhang, Lei ;
Crawford, Darrell H. G. .
PHARMACOLOGICAL RESEARCH, 2021, 169
[7]  
Burns N, 2025, Adv Drug Deliver Rev, P217
[8]   Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells [J].
Cha, Hwa Jun ;
Choi, Jung Hye ;
Parks, In Chul ;
Kim, Chun Ho ;
An, Sung Kwan ;
Kim, Tae Jin ;
Lee, Jae Ho .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 50 (04) :1279-1288
[9]  
Chen Guangping, 2022, J Cancer Ther, V13, P117, DOI 10.4236/jct.2022.133009
[10]   Genomic characteristics and drug screening among organoids derived fromnon-small celllung cancer patients [J].
Chen, Jing-Hua ;
Chu, Xiang-Peng ;
Zhang, Jia-Tao ;
Nie, Qiang ;
Tang, Wen-Fang ;
Su, Jian ;
Yan, Hong-Hong ;
Zheng, Hong-Ping ;
Chen, Ze-Xin ;
Chen, Xin ;
Song, Meng-Meng ;
Yi, Xin ;
Li, Pan-Song ;
Guan, Yan-Fang ;
Li, Gang ;
Deng, Chu-Xia ;
Rosell, Rafael ;
Wu, Yi-Long ;
Zhong, Wen-Zhao .
THORACIC CANCER, 2020, 11 (08) :2279-2290